{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:01:39Z","timestamp":1785240099100,"version":"3.55.0"},"reference-count":22,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prader\u2013Willi syndrome (PWS) is a complex genetic disorder characterized by severe hyperphagia, early-onset obesity, developmental delay, behavioral disturbances, and multiple endocrine dysfunctions. Clinical management is especially challenging when complicated by central nervous system tumors, which can further exacerbate hypothalamic dysfunction with consequent endocrine and metabolic complications. We present a clinically complex case of a girl with genetically confirmed PWS who developed medulloblastoma, requiring neurosurgical resection, craniospinal radiotherapy, and chemotherapy. Subsequent management was complicated by severe obesity, insulin resistance with impaired glucose tolerance, central hypothyroidism, adrenal insufficiency, and progressive neurological decline with severe obstructive sleep apnea. Key clinical challenges highlighted include the cautious re-initiation of growth hormone therapy post-oncological treatment, carefully balancing its metabolic and growth benefits, alongside multidisciplinary strategies to manage severe obesity-related endocrine and metabolic dysfunction. This case describes the co-existence of PWS and medulloblastoma, highlighting important clinical considerations that may inform management strategies and optimize outcomes in similarly complex situations.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag177","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:41:40Z","timestamp":1782848500000},"source":"Crossref","is-referenced-by-count":0,"title":["Challenges in managing endocrine and metabolic dysfunction in a child with Prader\u2013Willi syndrome and medulloblastoma"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5330","authenticated-orcid":false,"given":"Daniel","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Pediatric Endocrinology, Great Ormond Street Hospital , London WC1N 3BH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3426-2511","authenticated-orcid":false,"given":"Harshini","family":"Katugampola","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Great Ormond Street Hospital , London WC1N 3BH ,","place":["UK"]},{"name":"Genetics and Genomic Medicine Programme, UCL Great Ormond Street Institute of Child Health , London WC1N 1EH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul T","family":"Dattani","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Great Ormond Street Hospital , London WC1N 3BH ,","place":["UK"]},{"name":"Genetics and Genomic Medicine Programme, UCL Great Ormond Street Institute of Child Health , London WC1N 1EH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"1","key":"2026072807154201800_luag177-B1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tem.2003.11.003","article-title":"Prader-Willi syndrome: advances in genetics, pathophysiology and treatment","volume":"15","author":"Goldstone","year":"2004","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"2026072807154201800_luag177-B2","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s40618-021-01574-9","article-title":"Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches","volume":"44","author":"Muscogiuri","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2026072807154201800_luag177-B3","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1002\/mgg3.514","article-title":"A multidisciplinary approach to the clinical management of Prader-Willi syndrome","volume":"7","author":"Duis","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"2026072807154201800_luag177-B4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-642-38007-5_2","article-title":"Obesity, energy balance, and cancer: a mechanistic perspective","volume":"159","author":"Hursting","year":"2014","journal-title":"Cancer Treat Res"},{"issue":"12","key":"2026072807154201800_luag177-B5","doi-asserted-by":"crossref","first-page":"e1720","DOI":"10.1210\/clinem\/dgad312","article-title":"Malignancies in Prader-Willi syndrome: results from a large international cohort and literature review","volume":"108","author":"Pellikaan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026072807154201800_luag177-B6","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1210\/jcem.87.5.8503","article-title":"Oral hydrocortisone administration in children with classic 21-hydroxylase deficiency leads to more synchronous joint GH and cortisol secretion","volume":"87","author":"Charmandari","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026072807154201800_luag177-B7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1067\/mpd.2003.81","article-title":"Myeloid leukemia in Prader-Willi syndrome","volume":"142","author":"Davies","year":"2003","journal-title":"J Pediatr"},{"key":"2026072807154201800_luag177-B8","article-title":"Register-based and genetic studies of Prader-Willi syndrome show a high frequency of gonadal tumors and a possible mechanism for tumorigenesis through imprinting relaxation","volume":"10","author":"Maya-Gonz\u00e1lez","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2026072807154201800_luag177-B9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev.med.080708.082713","article-title":"Biological mechanisms linking obesity and cancer risk: new perspectives","volume":"61","author":"Roberts","year":"2010","journal-title":"Annu Rev Med"},{"issue":"9","key":"2026072807154201800_luag177-B10","doi-asserted-by":"crossref","DOI":"10.3390\/nu14091950","article-title":"Prader-Willi syndrome: possibilities of weight gain prevention and treatment","volume":"14","author":"Erhardt","year":"2022","journal-title":"Nutrients"},{"issue":"9","key":"2026072807154201800_luag177-B11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1515\/jpem.2010.150","article-title":"Growth hormone therapy and the risk of tumor recurrence after brain tumor treatment in children","volume":"23","author":"Rohrer","year":"2010","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"7","key":"2026072807154201800_luag177-B12","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1210\/jcem.87.7.8606","article-title":"Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study","volume":"87","author":"Sklar","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026072807154201800_luag177-B13","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.jocn.2014.04.016","article-title":"Growth hormone treatment and risk of recurrence or development of secondary neoplasms in survivors of pediatric brain tumors","volume":"21","author":"Wang","year":"2014","journal-title":"J Clin Neurosci"},{"issue":"4","key":"2026072807154201800_luag177-B14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1530\/EJE-20-0369","article-title":"Influence of growth hormone therapy on the occurrence of a second neoplasm in survivors of childhood cancer","volume":"183","author":"Thomas-Teinturier","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026072807154201800_luag177-B15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s11102-021-01173-0","article-title":"Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice","volume":"24","author":"Boguszewski","year":"2021","journal-title":"Pituitary"},{"issue":"3","key":"2026072807154201800_luag177-B16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1210\/er.2018-00092","article-title":"Long-term endocrine and metabolic consequences of Cancer treatment: a systematic review","volume":"40","author":"Gebauer","year":"2019","journal-title":"Endocr Rev"},{"issue":"11","key":"2026072807154201800_luag177-B17","first-page":"849","article-title":"Obesity and metabolic disease after childhood Cancer","volume":"29","author":"Barnea","year":"2015","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"2026072807154201800_luag177-B18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.20945\/2359-3997000000248","article-title":"Prader-Willi syndrome: endocrine manifestations and management","volume":"64","author":"Alves","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"2026072807154201800_luag177-B19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2147\/DMSO.S141352","article-title":"Obesity management in Prader-Willi syndrome: current perspectives","volume":"11","author":"Crin\u00f2","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026072807154201800_luag177-B20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1069164","article-title":"Association of childhood and adolescence obesity with incidence and mortality of adulthood cancers. A systematic review and meta-analysis","volume":"14","author":"Mohammadian Khonsari","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026072807154201800_luag177-B21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S2213-8587(20)30019-X","article-title":"Adolescent obesity and midlife cancer risk: a population-based cohort study of 2\u00b73 million adolescents in Israel","volume":"8","author":"Furer","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026072807154201800_luag177-B22","doi-asserted-by":"crossref","DOI":"10.1111\/obr.12992","article-title":"Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: a narrative review","volume":"21","author":"Tan","year":"2020","journal-title":"Obes Rev"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/9\/luag177\/70253768\/luag177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/9\/luag177\/70253768\/luag177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:15:53Z","timestamp":1785237353000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag177\/8743974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7,27]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag177","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,27]]},"article-number":"luag177"}}